, Volume 15, Issue 4, pp 539–551 | Cite as

Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study

  • Carla Giordano
  • Alessandro Ciresi
  • Marco Calogero Amato
  • Rosario Pivonello
  • Renata Simona Auriemma
  • Ludovica Francesca Stella Grasso
  • Aldo Galluzzo
  • Annamaria Colao


To evaluate the metabolic effects of first-line somatostatin analogues or surgery in acromegaly. Retrospective, comparative, 12-month follow-up. Two hundred and thirty one patients (123 men, age 47.32 ± 14.63 years) with active acromegaly, first line treatments were somatostatin analogues in 151 (65.4%) and surgery in 80 (34.6%). Metabolic syndrome (MS) parameters, glucose, insulin and GH during oral glucose tolerance test, stimulated insulin sensitivity by insulin sensitivity index (ISI Matsuda), early and total insulin-secretion rate by insulinogenic index and AUCINS, visceral adiposity function, expressed by visceral adipose index (VAI). Somatostatin analogues treatment improved all MS parameters and significantly reduced fasting glucose (P < 0.001), HbA1c (P = 0.014) and the prevalence of DM (P = 0.003) when disease control was achieved. Both somatostatin analogues and surgery improved ISI Matsuda (P < 0.001) and reduced AUCINS (P < 0.001) and VAI (P < 0.001 and P = 0.003, respectively). Only in controlled somatostatin analogues-treated patients a significant reduction in insulinogenic index (P = 0.010) was observed. ISI Matsuda showed a significant independent correlation with IGF-1 levels (β = −0.258; P = 0.001) and VAI score (β = −0.430; P < 0.001). VAI was independently correlated with IGF-1 (β = 0.183; P = 0.004). Both somatostatin analogues and surgery can safely be used as first-line therapy in acromegaly, without any untoward effects on glucose tolerance. The control of acromegaly is the main determinant of beneficial effects on general features of insulin sensitivity. VAI could represent an additional link between disease control and insulin sensitivity.


GH IGF-I Acromegaly Pituitary Glucose Insulin 



This study has been supported in part by grants of Italian Minister of Research (MIUR)”, no. 2003068735.

Conflict of interest

Annamaria Colao is recipient of unrestricted support from Ipsen, Novartis and Pfizer for studies in neuroendocrinology. The other authors have nothing to disclose.

Ethical standards

The authors declare that the experiments comply with the current Italian laws.


  1. 1.
    Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558–2573PubMedCrossRefGoogle Scholar
  2. 2.
    Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189–3202PubMedCrossRefGoogle Scholar
  3. 3.
    Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102–152PubMedCrossRefGoogle Scholar
  4. 4.
    Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242–1247PubMedGoogle Scholar
  5. 5.
    Jayasena C, Comninos A, Clarke H, Donaldson M, Meeran K, Dhillo W (2011) The effects of long-term GH and IGF-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf) 75:220–225CrossRefGoogle Scholar
  6. 6.
    Colao A, Baldelli R, Marzullo P, Ferretti F, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199PubMedCrossRefGoogle Scholar
  7. 7.
    Sherlock M, Woods C, Sheppard MC (2011) Medical therapy in acromegaly. Nat Rev Endocrinol 7(5):291–300Google Scholar
  8. 8.
    Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants’ (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058PubMedCrossRefGoogle Scholar
  9. 9.
    Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247–271PubMedCrossRefGoogle Scholar
  10. 10.
    Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, SMS995B2401 Study Group (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859–868CrossRefGoogle Scholar
  11. 11.
    Alberti KGMM, Christensen SE, Christensen NJ, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K, Orskov H (1973) Inhibition of insulin secretion by somatostatin. Lancet 2:1299–1301PubMedCrossRefGoogle Scholar
  12. 12.
    Johansson C, Wisen O, Efendic S, Uvnas-Wallenstein K (1981) Effect of somatostatin on gastrointestinal propagation and absorption of oral glucose in man. Digestion 22:126–137PubMedCrossRefGoogle Scholar
  13. 13.
    Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J (2006) Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155:73–78PubMedCrossRefGoogle Scholar
  14. 14.
    Pereira AM, Biermasz NR, Roelfsema F, Romijn JA (2005) Pharmacologic therapies for acromegaly. A review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4:43–53PubMedCrossRefGoogle Scholar
  15. 15.
    Saitoh Y, Ohnishi T, Arita N (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549–555CrossRefGoogle Scholar
  16. 16.
    Karaca Z, Tanriverdi F, Elbuken G, Cakir I, Donmez H, Selcuklu A, Durak A, Dokmetas H, Colak R, Unluhizarci K, Kelestimur F (2011) Comparison of primary octreotide-LAR and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol (Oxf). doi: 10.1111/j.1365-2265.2011.04106.x [Epub ahead of print]
  17. 17.
    Tzanela M, Vassiliadi DA, Gavalas N, Szabo A, Margelou E, Valatsou A, Vassilopoulos C (2011) Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf). doi: 10.1111/j.1365-2265.2011.03996.x [Epub ahead of print]
  18. 18.
    Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128PubMedCrossRefGoogle Scholar
  19. 19.
    Chen HS, Wu TE, Jap TS, Hsiao LC, Lin HD, Lee SH, Lin SH (2011) Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery. Horm Metab Res 43:433–439PubMedCrossRefGoogle Scholar
  20. 20.
    Cambuli VM, Galdiero M, Mastinu M, Pigliaru F, Auriemma RS, Ciresi A, Pivonello R, Amato M, Giordano C, Mariotti S, Colao A, Baroni MG (2011) Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. J Endocrinol Invest [Epub ahead of print]Google Scholar
  21. 21.
    Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, Pivonello R (2009) Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94:2907–2914PubMedCrossRefGoogle Scholar
  22. 22.
    Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93:2639–2646PubMedCrossRefGoogle Scholar
  23. 23.
    Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-years observational, open, prospective study. J Clin Endocrinol Metab 94:528–537PubMedCrossRefGoogle Scholar
  24. 24.
    Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, For the AlkaMeSy Study Group (2010) Visceral Adiposity Index (VAI): a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922PubMedCrossRefGoogle Scholar
  25. 25.
    Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, The participants of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group (2006) J Endocrinol Invest 29:1017–1020Google Scholar
  26. 26.
    Colao A, Lombardi G (1998) Growth hormone and prolactin excess. Lancet 352:1455–1461PubMedCrossRefGoogle Scholar
  27. 27.
    Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus Group (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148PubMedCrossRefGoogle Scholar
  28. 28.
    American Association of Clinical Endocrinologists (2000) The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management—2000 update. Endocr Pract 6(1):43–84Google Scholar
  29. 29.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin in man. Diabetologia 28:412–419PubMedCrossRefGoogle Scholar
  30. 30.
    Matsuda M, De Fronzo RA (2001) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 24:460–464CrossRefGoogle Scholar
  31. 31.
    Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301PubMedCrossRefGoogle Scholar
  32. 32.
    Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–246PubMedCrossRefGoogle Scholar
  33. 33.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP). J Am Med Assoc 285:2486–2497Google Scholar
  34. 34.
    Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529PubMedCrossRefGoogle Scholar
  35. 35.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancrajan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779–2786PubMedCrossRefGoogle Scholar
  36. 36.
    Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Foglia G (1995) Effects of treatment with octreotide in acromegalic patients—a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 133:430–439PubMedCrossRefGoogle Scholar
  37. 37.
    Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D’Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol 59:492–499CrossRefGoogle Scholar
  38. 38.
    Sonksen PH, Greenwood FC, Ellis JP, Lowy C, Rutherford A, Nabarro JD (1967) Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 27:1418–1430PubMedCrossRefGoogle Scholar
  39. 39.
    Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ (1992) Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 36:271–279CrossRefGoogle Scholar
  40. 40.
    Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a meta-analysis acromegaly studies. J Clin Endocrinol Metab 94:1500–1508PubMedCrossRefGoogle Scholar
  41. 41.
    Lorenzo C, Haffner SM, Stancáková A, Laakso M (2010) Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic Finnish offspring of type 2 diabetic individuals. J Clin Endocrinol Metab 95:5082–5090PubMedCrossRefGoogle Scholar
  42. 42.
    Bengtsson BA, Brummer RJ, Bosaeus I (1990) Growth hormone and body composition. Horm Res 33(Suppl 4):19–24Google Scholar
  43. 43.
    Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5:181–183PubMedCrossRefGoogle Scholar
  44. 44.
    Richelsen B (1997) Action of growth hormone in adipose tissue. Horm Res 48(Suppl 5):105–110Google Scholar
  45. 45.
    Yang S, Mulder H, Holm C, Eden S (2004) Effects of growth hormone on the function of beta-adrenoceptor subtypes in rat adipocytes. Obes Res 12:330–339PubMedCrossRefGoogle Scholar
  46. 46.
    Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, Gallagher D (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93:2334–2343PubMedCrossRefGoogle Scholar
  47. 47.
    Unger RH, Scherer PE (2010) Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 21:345–352PubMedCrossRefGoogle Scholar
  48. 48.
    Garg A (2000) Lipodystrophies. Am J Med 108:143–152PubMedCrossRefGoogle Scholar
  49. 49.
    Asilmaz E, Cohen P, Miyazaki M, Dobrzyn P, Ueki K, Fayzikhodjaeva G, Soukas AA, Kahn CR, Ntambi JM, Socci ND, Friedman JM (2004) Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 113:414–424PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Carla Giordano
    • 1
  • Alessandro Ciresi
    • 1
  • Marco Calogero Amato
    • 1
  • Rosario Pivonello
    • 2
  • Renata Simona Auriemma
    • 2
  • Ludovica Francesca Stella Grasso
    • 2
  • Aldo Galluzzo
    • 1
  • Annamaria Colao
    • 2
  1. 1.Department of Endocrinology and Metabolic Diseases, DOSACUniversity of PalermoPalermoItaly
  2. 2.Department of Molecular and Clinical Endocrinology and Oncology, Section of EndocrinologyUniversity “Federico II” of NaplesNaplesItaly

Personalised recommendations